Nastech to concentrate on RNAi technology, change name

06/10/2008 | Boston Globe (tiered subscription model), The

Nastech Pharmaceutical Co. announced that it will change its name to mdRNA, effective June 23, as it shifts its focus to RNAi technology. RNAi-based therapies, also called gene-silencing treatments, will be available sooner than expected, driven by industry interest and the technology's rapid progression, said incoming mdRNA CEO J. Michael French.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID